JPH0667852B2 - 多価高度免疫グロブリン製剤およびその製法 - Google Patents
多価高度免疫グロブリン製剤およびその製法Info
- Publication number
- JPH0667852B2 JPH0667852B2 JP61102222A JP10222286A JPH0667852B2 JP H0667852 B2 JPH0667852 B2 JP H0667852B2 JP 61102222 A JP61102222 A JP 61102222A JP 10222286 A JP10222286 A JP 10222286A JP H0667852 B2 JPH0667852 B2 JP H0667852B2
- Authority
- JP
- Japan
- Prior art keywords
- gram
- coli
- negative
- antibody titer
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 241000588724 Escherichia coli Species 0.000 claims abstract description 35
- 239000000427 antigen Substances 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims abstract description 16
- 108091007433 antigens Proteins 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- 244000000058 gram-negative pathogen Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 244000000059 gram-positive pathogen Species 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 5
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000035931 haemagglutination Effects 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- 241001312524 Streptococcus viridans Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims 1
- 240000008042 Zea mays Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 17
- 102000018358 immunoglobulin Human genes 0.000 abstract description 17
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract description 6
- 238000007796 conventional method Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 8
- 230000000521 hyperimmunizing effect Effects 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000256215 Spongomorpha aeruginosa Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853516119 DE3516119A1 (de) | 1985-05-04 | 1985-05-04 | Polyvalentes hyperimmunglobulin-praeparat |
| DE3516119.1 | 1985-05-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6230729A JPS6230729A (ja) | 1987-02-09 |
| JPH0667852B2 true JPH0667852B2 (ja) | 1994-08-31 |
Family
ID=6269874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61102222A Expired - Lifetime JPH0667852B2 (ja) | 1985-05-04 | 1986-05-06 | 多価高度免疫グロブリン製剤およびその製法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4965068A (OSRAM) |
| EP (1) | EP0201004B1 (OSRAM) |
| JP (1) | JPH0667852B2 (OSRAM) |
| AT (1) | ATE87216T1 (OSRAM) |
| DE (2) | DE3516119A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3852950T2 (de) * | 1988-12-22 | 1995-06-14 | Baxter Diagnostics Inc | Lipohaptene und Verwendung trägergebundener Lipohaptene im Immuntest. |
| US5093117A (en) * | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| WO1992016230A1 (en) * | 1991-03-15 | 1992-10-01 | Univax Biologics Incorporated | Lipid a analog/immunogenic carrier conjugates, the use thereof as vaccines and polyvalent hyperimmune gammaglobulins |
| US5233024A (en) * | 1991-04-09 | 1993-08-03 | The Brigham & Women's Hospital | Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use |
| JPH08508240A (ja) * | 1993-01-12 | 1996-09-03 | ジョージ グリスティーナ，アンソニー | 受動免疫の直接的濃厚伝達のための方法および組成物 |
| RU2150960C1 (ru) * | 1995-07-18 | 2000-06-20 | Томский научно-исследовательский институт вакцин и сывороток НПО "Вирион" | Способ получения иммуноглобулина противодифтерийного человека |
| ES2170788T3 (es) * | 1995-09-22 | 2002-08-16 | Zlb Bioplasma Ag | Procedimiento para la obtencion de inmunoglobulinas a partir de fracciones que resultan de plasma sanguineo humano. |
| US6610293B1 (en) * | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US6692739B1 (en) | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| NL1019143C2 (nl) * | 2001-10-08 | 2003-04-09 | Nutricia Nv | Farmaceutisch product of voedingssupplement en daarbij te gebruiken tussenproduct. |
| CA2563904A1 (en) * | 2004-02-18 | 2005-08-25 | Plasma Ventures Pty Ltd | Isolated plasma and method for hyperimmunisation and plasma collection |
| US20080260777A1 (en) * | 2007-04-19 | 2008-10-23 | Sotomayor Konky | Composition and method for controlling intestinal pathogenic organisms |
| US7935355B2 (en) * | 2007-04-19 | 2011-05-03 | Nutritional Health Institute Laboratories, Llc | Composition and method for controlling intestinal pathogenic organisms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE14333C (de) * | P. MAC LELLAN in Glasgow | Gummimatte | ||
| BE791489A (fr) * | 1971-11-17 | 1973-05-16 | Max Planck Gesellschaft | Agent immunisant, procede de fabrication et utilisation d'un tel agent |
| US4029762A (en) * | 1971-11-17 | 1977-06-14 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Lipid A-preparation |
| US4174388A (en) * | 1977-02-14 | 1979-11-13 | Merck & Co., Inc. | Method for preparing hepatitis B immune globulin |
| US4428931A (en) * | 1982-03-15 | 1984-01-31 | Merck & Co., Inc. | Bacterial toxoids and gram-negative immune globulin therefrom |
| US4587121A (en) * | 1983-06-14 | 1986-05-06 | Miles Laboratories, Inc. | High titer Pseudomonas immune serum globulin |
-
1985
- 1985-05-04 DE DE19853516119 patent/DE3516119A1/de active Granted
-
1986
- 1986-04-25 EP EP86105706A patent/EP0201004B1/de not_active Expired - Lifetime
- 1986-04-25 AT AT86105706T patent/ATE87216T1/de not_active IP Right Cessation
- 1986-04-25 DE DE8686105706T patent/DE3688100D1/de not_active Expired - Fee Related
- 1986-05-06 JP JP61102222A patent/JPH0667852B2/ja not_active Expired - Lifetime
-
1989
- 1989-06-23 US US07/370,118 patent/US4965068A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE3516119C2 (OSRAM) | 1993-07-01 |
| EP0201004A3 (en) | 1988-05-25 |
| US4965068A (en) | 1990-10-23 |
| ATE87216T1 (de) | 1993-04-15 |
| JPS6230729A (ja) | 1987-02-09 |
| DE3688100D1 (de) | 1993-04-29 |
| DE3516119A1 (de) | 1986-11-06 |
| EP0201004B1 (de) | 1993-03-24 |
| EP0201004A2 (de) | 1986-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrews et al. | Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge | |
| Agüero et al. | A plasmid-encoded outer membrane protein, TraT, enhances resistance of Escherichia coli to phagocytosis | |
| EP0129147B1 (en) | High titer pseudomonas immune serum globulin and method of making same | |
| US6322788B1 (en) | Anti-bacterial antibodies and methods of use | |
| JPH0667852B2 (ja) | 多価高度免疫グロブリン製剤およびその製法 | |
| JP4743928B2 (ja) | 処方物 | |
| JPH04352729A (ja) | ウシ科動物の抗体を用いた哺乳動物の受動免疫化 | |
| US4816253A (en) | Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
| MX2007003400A (es) | Composicion inmunogena. | |
| NZ239643A (en) | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. | |
| EP0694309A2 (en) | Vaccine, antigens and antibodies containing compound for inhibiting and preventing induced staphylococcus infection | |
| US4567041A (en) | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
| CA2592627C (en) | Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide | |
| US4493825A (en) | Purified and antigenically selective vaccines for domestic animals | |
| DE3882781T3 (de) | Impfstoff gegen Pasteurella. | |
| JPH11507805A (ja) | 非細胞性百日咳ワクチンおよびその製造方法 | |
| DE69232483T2 (de) | Mycobacteriumprotein und dessen verwendung | |
| Hellman et al. | Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous gram-negative bacteria | |
| CA2117480A1 (en) | Directed human immune globulin for the prevention and treatment of staphylococcal infections | |
| DE69524626T2 (de) | Äusseres hauptmembranprotein cd von moraxella | |
| Dolby et al. | The antibody activities of 19S and 7S fractions from rabbit antisera to Bordetella pertussis | |
| AU774649B2 (en) | Vaccine preparations containing attenuated toxin | |
| Cross | Intravenous immunoglobins (IVIGs) to prevent and treat infectious diseases | |
| Stinson et al. | Binding of Streptococcus mutans antigens to heart and kidney basement membranes | |
| EP1370289A2 (de) | Verfahren zur herstellung eines autologen antikörpers enthaltenden impfstoffes |